The CMT Research Foundation is collaborating with a scientist to identify fat (lipid) nanoparticles that might work as a vehicle for delivering gene therapies to the specific cells affected in people with Charcot-Marie-Tooth (CMT) disease. The partnership with James Dahlman, PhD, aims to overcome a major obstacle to new therapies for CMT patients. Dahlman is an assistant professor at the Georgia Institute of Technology and Emory School of Medicine, and an expert in the field of…

You must be logged in to read/download the full post.